Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | GRM1 | Q13255 | 5/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13610798 | 0.78 | KDM4E (0.33) | KDM4EPKMALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL10856198 | 0.77 | — | — | |
| SCHEMBL107379 | 0.77 | — | — | |
| SCHEMBL13379440 | 0.76 | KDM4E (0.32) | KDM4EPKM | |
| SCHEMBL3056401 | 0.75 | — | — | |
| SCHEMBL13485367 | 0.75 | — | — | |
| SCHEMBL11166070 | 0.73 | NAMPT (0.43) | NAMPTKDM4EPKMGRM1GRM4 | |
| SCHEMBL13485303 | 0.72 | NAMPT (0.53) | NAMPTKDM4EPKMGRM1GRM4 | |
| SCHEMBL860103 | 0.72 | NPSR1 (0.46) | NAMPTKDM4EPKMGRM1 | |
| SCHEMBL13040029 | 0.72 | NAMPT (0.42) | NAMPTKDM4EPKMGRM1GRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090280106-A1 | Pituitary adenylate cyclase acivating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090280106-A1 | Pituitary adenylate cyclase acivating peptide (pacap) receptor (vpac2) agonists and their pharmacological methods of use | ADCYAP1R1, VIPR2, ADCY2 | NAMPT 668/4885KDM4E 2974/4885PKM 1528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.